Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Mar 15;17(7):892-902.
doi: 10.7150/ijms.43079. eCollection 2020.

Direct-acting Antiviral in the Treatment of Chronic Hepatitis C: Bonuses and Challenges

Haiyan Zeng  1   2 , Lei Li  2 , Zhouhua Hou  1 , Yapeng Zhang  2 , Zhongxiang Tang  2 , Shuiping Liu  1   2
Affiliations
Review

Direct-acting Antiviral in the Treatment of Chronic Hepatitis C: Bonuses and Challenges

Haiyan Zeng et al. Int J Med Sci. .

Abstract

Owing to the rapid development and wide clinical application of direct acting antiviral (DAA) drugs in the treatment of hepatitis C virus (HCV) infection, the era of interferon-based therapy has almost come to an end. Cumulative studies show that DAA therapy renders high cure efficiency (>90%) and good safety profile, and may even bring some unexpected benefits to the patients. However, some issues of concern arise, one of which is the resistance mutation of HCV genome leading to failure of treatment. With the aim of providing some meaningful references for the treatment of chronic hepatitis C (CHC), this article summarizes the research progress on benefits of DAA accompanied by viral clearance in the treatment of chronic hepatitis and the drug resistance.

Keywords: direct acting antiviral (DAA); hepatitis C virus (HCV); resistance-associated substitutions (RAS); sustained virological response (SVR).

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interest exists.

Figures

Figure 1
Figure 1
Hepatitis C virus (HCV)-associated glucose and lipid metabolic changes . GLUT2, glucose transporter 2; INS, insulin; IRS, insulin receptor substrate; mTOR, mammalian target of rapamycin; SOCS3, suppressor of cytokine-signalling protein; AKT, protein kinase B (Akt); FoxO1,forkhead box protein O1, transcription factor; PEPCK, phosphoenolpyruvate carboxykinase; G6Pase, glucose-6-phosphatase; SREBP, sterol regulatory element-binding protein; SRE, sterol regulatory element; PPAR, peroxisome proliferator-activated receptor; PPRE, PPAR response element; NS5A, HCV non-structural protein 5A;VLDL, very-low-density lipoprotein cholesterol; ApoB, apolipoprotein B; TG, triglycerides; FA, fatty acid.
Figure 2
Figure 2
Change of immune cell function after HCV clearance by successful DAA treatment.
See this image and copyright information in PMC

References

    1. Polaris Observatory HCVC. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017;2:161–76. - PubMed
    1. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013;57:1333–42. - PubMed
    1. Li G, De Clercq E. Current therapy for chronic hepatitis C: The role of direct-acting antivirals. Antiviral Res. 2017;142:83–122. - PMC - PubMed
    1. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R. et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958–65. - PubMed
    1. Cuypers L, Ceccherini-Silberstein F, Van Laethem K, Li G, Vandamme AM, Rockstroh JK. Impact of HCV genotype on treatment regimens and drug resistance: a snapshot in time. Rev Med Virol. 2016;26:408–34. - PubMed